BACKGROUND: We have developed xenografts of human glioblastoma (GBM) and established the baseline growth parameters and histopathological features of these tumors. MATERIALS- METHODS: Cells from 4 different human GBM cell lines were injected into the right caudate-putamen of brain in athymic rats. We measured tumor weights and the estimated survival time of each rat. RESULTS- CONCLUSION: U-251 MG and U-87 MG cells produced solid intracerebral tumors with a 100% tumor take rate, while SF-767 and SF-126 cells did not grow in the brains of athymic rats. Under the conditions employed, U-87 MG tumors grew faster than U-251 MG tumors, but both types of tumors exhibited reproducible growth characteristics from animal to animal. There was heterogeneity in the growth characteristics and histologies between the 2 tumor types, indicating that these tumor models might be useful for simulating some of the heterogeneity that occurs between GBM in humans.
BACKGROUND: We have developed xenografts of humanglioblastoma (GBM) and established the baseline growth parameters and histopathological features of these tumors. MATERIALS- METHODS: Cells from 4 different human GBM cell lines were injected into the right caudate-putamen of brain in athymic rats. We measured tumor weights and the estimated survival time of each rat. RESULTS- CONCLUSION: U-251 MG and U-87 MG cells produced solid intracerebral tumors with a 100% tumor take rate, while SF-767 and SF-126 cells did not grow in the brains of athymic rats. Under the conditions employed, U-87 MG tumors grew faster than U-251 MG tumors, but both types of tumors exhibited reproducible growth characteristics from animal to animal. There was heterogeneity in the growth characteristics and histologies between the 2 tumor types, indicating that these tumor models might be useful for simulating some of the heterogeneity that occurs between GBM in humans.
Authors: Myriam M Chaumeil; Peder E Z Larson; Hikari A I Yoshihara; Olivia M Danforth; Daniel B Vigneron; Sarah J Nelson; Russell O Pieper; Joanna J Phillips; Sabrina M Ronen Journal: Nat Commun Date: 2013 Impact factor: 14.919
Authors: Myriam M Chaumeil; Tomoko Ozawa; IlWoo Park; Kristen Scott; C David James; Sarah J Nelson; Sabrina M Ronen Journal: Neuroimage Date: 2011-07-23 Impact factor: 6.556
Authors: Ilwoo Park; Peder E Z Larson; Matthew L Zierhut; Simon Hu; Robert Bok; Tomoko Ozawa; John Kurhanewicz; Daniel B Vigneron; Scott R Vandenberg; C David James; Sarah J Nelson Journal: Neuro Oncol Date: 2010-01-25 Impact factor: 12.300
Authors: Myriam M Chaumeil; Beatrice Gini; Huijun Yang; Akio Iwanami; Subramaniam Sukumar; Tomoko Ozawa; Russel O Pieper; Paul S Mischel; C David James; Mitchel S Berger; Sabrina M Ronen Journal: Neuro Oncol Date: 2012-06-04 Impact factor: 12.300
Authors: Jingli Wang; Jack Klem; Jan B Wyrick; Tomoko Ozawa; Erin Cunningham; Jay Golinveaux; Max J Allen; Kathleen R Lamborn; Dennis F Deen Journal: Neoplasia Date: 2003 Jul-Aug Impact factor: 5.715
Authors: Rintaro Hashizume; Tomoko Ozawa; Sergei M Gryaznov; Andrew W Bollen; Kathleen R Lamborn; William H Frey; Dennis F Deen Journal: Neuro Oncol Date: 2008-02-20 Impact factor: 12.300
Authors: Tomoko Ozawa; Sergei M Gryaznov; Lily J Hu; Krisztina Pongracz; Raquel A Santos; Andrew W Bollen; Kathleen R Lamborn; Dennis F Deen Journal: Neuro Oncol Date: 2004-07 Impact factor: 12.300
Authors: Rintaro Hashizume; Tomoko Ozawa; Eduard B Dinca; Anuradha Banerjee; Michael D Prados; Charles D James; Nalin Gupta Journal: J Neurooncol Date: 2009-07-08 Impact factor: 4.130